Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

The Trump administration has terminated National Institutes of Health (NIH) grants totaling more than $1.8 billion, and the National Cancer Institute (NCI) is among the top 5 institutes with the most ...

Washington state’s attorney general alleges the Trump administration has violated a preliminary injunction intended to stop it from cutting research funding.

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

Experts say the Trump administration's cancellation of more than $800 million in research focused on LGBTQ patients could harm public health.

The risk of death from kidney cancer has decreased in the United States in recent years, but the risk varies by sex, race, and ethnicity, according to research published in The Oncologist.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...

Two studies examining relationships between measures of kidney function and adverse events after platinum-based chemotherapy were presented as late-breaking abstracts at the National Kidney Foundation ...

Despite a congressional mandate to expand care for veterans, internal Veterans Affairs messages obtained by ProPublica paint a stark portrait of how chaotic cost cutting has already imperiled tests of ...

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.